Search Results - Jeffrey W. Tyner

Refine Results
  1. 1
    Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals

    Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals by Jeffrey W. Tyner

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    What's different about atypical CML and chronic neutrophilic leukemia?

    What's different about atypical CML and chronic neutrophilic leukemia? by Kim-Hien T. Dao, Jeffrey W. Tyner

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Genomics of chronic neutrophilic leukemia

    Genomics of chronic neutrophilic leukemia by Julia E. Maxson, Jeffrey W. Tyner

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia

    Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia by Emmanuella Oyogoa, Elie Traer, Jeffrey W. Tyner, Curtis A. Lachowiez

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment

    The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment by Jason Gotlib, Julia E. Maxson, Tracy I. George, Jeffrey W. Tyner

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia

    Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia by Shovik Bandyopadhyay, Junjie Li, Elie Traer, Jeffrey W. Tyner, Amy Zhou, Stephen T. Oh, Ji‐Xin Cheng

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

    Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia by Vincent T. Bicocca, Bill H. Chang, Behzad Kharabi Masouleh, Markus Müschen, Marc Loriaux, Brian J. Druker, Jeffrey W. Tyner

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerization

    Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerizatio... by Julia E. Maxson, Samuel B. Luty, Jason D. MacManiman, Melissa L. Abel, Brian J. Druker, Jeffrey W. Tyner

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

    Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia by Kim-Hien T. Dao, Magdolna Solti, Julia E. Maxson, Elliott F. Winton, Richard D. Press, Brian J. Druker, Jeffrey W. Tyner

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

    Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations by Elie Traer, Nathalie Javidi‐Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Jacqueline Martinez, Jeffrey W. Tyner, Melissa Wong, Brian J. Druker

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia

    Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia by Vishesh Khanna, Scott T. Pierce, Kim‐Hien T. Dao, Cristina E. Tognon, David E. Hunt, Brian Junio, Jeffrey W. Tyner, Brian J. Druker

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance

    Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance by Shelton A. Viola, Elie Traer, Jianya Huan, Noah I. Hornick, Jeffrey W. Tyner, Anupriya Agarwal, Marc Loriaux, Brian H. Johnstone, Peter Kurre

    Published 2015
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  13. 13
    Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

    Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma by Matthew B. Siegel, Selina Qiuying Liu, Monika A. Davare, Stephen E. Spurgeon, Marc Loriaux, Brian J. Druker, Emma C. Scott, Jeffrey W. Tyner

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

    Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia by Haijiao Zhang, Yusuke Nakauchi, Thomas Köhnke, Melissa Stafford, Daniel Bottomly, Rozario Thomas, Beth Wilmot, Shannon K. McWeeney, Ravindra Majeti, Jeffrey W. Tyner

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

    FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia by Elie Traer, Jacqueline Martinez, Nathalie Javidi‐Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Tibor Kovacsovics, Jeffrey W. Tyner, Melissa H. Wong, Brian J. Druker

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia

    Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia by Jessica T. Leonard, Joelle Rowley, Christopher A. Eide, Elie Traer, Brandon Hayes‐Lattin, Marc Loriaux, Stephen E. Spurgeon, Brian J. Druker, Jeffrey W. Tyner, Bill H. Chang

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations

    Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations by Su Lin Lim, Alisa Damnernsawad, Pavithra Shyamsunder, Wee Joo Chng, Bing Han, Liang Xu, Jian Pan, Pushkar Dakle, Serhan Alkan, Jeffrey W. Tyner, H. Phillip Koeffler

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia

    CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia by Animesh Pardanani, Terra L. Lasho, Rebecca R. Laborde, Michelle A. Elliott, C. Hanson, Ryan A. Knudson, Rhett P. Ketterling, Julia E. Maxson, Jeffrey W. Tyner, A Tefferi

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

    Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance by Nathalie Javidi‐Sharifi, Elie Traer, Jacqueline Martinez, Anu Gupta, Takehiro Taguchi, Jennifer Dunlap, Michael C. Heinrich, Christopher L. Corless, Brian P. Rubin, Brian J. Druker, Jeffrey W. Tyner

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

    CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms by Jeffrey W. Tyner, Thomas G.P. Bumm, Jutta Deininger, Lisa J. Wood, Karl J. Aichberger, Marc Loriaux, Brian J. Druker, Christopher J. Burns, Emmanuelle Fantino, Michael W. Deininger

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: